60 DEGREES PHARMACEUTICALS, INC. Income Statement
SXTP|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
60 DEGREES PHARMACEUTICALS, INC. reported $607,574 in revenue and $8M in net loss for FY2025. Revenue has grown at a 65.0% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -4.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $607.6K | $253.6K | $223.2K |
| Cost of Revenue | $384.8K | $474.6K | $432.4K |
| Gross Profit | $222.8K | -$221.0K | -$209.2K |
| SG&A Expense | $5.0M | $4.2M | $1.3M |
| R&D Expense | $5.0M | $691.8K | $525.6K |
| Operating Income | -$9.7M | -$5.2M | -$1.8M |
| Interest Expense | - | $66.6K | $4.0M |
| Income Tax | $0 | $250 | $500 |
| Net Income | -$7.9M | -$3.8M | -$6.2M |
| EPS (Basic) | -$74.17 | -$59.18 | -$2.61 |
| EPS (Diluted) | -$74.17 | -$59.18 | -$2.61 |
| Shares Outstanding | 21.2M | 96.8K | 2.4M |
| Gross Margin | 36.7% | -87.2% | -93.7% |
| Operating Margin | -1599.0% | -2032.8% | -784.2% |
| Profit Margin | -1308.0% | -1485.1% | -2769.5% |